IGHE and asthma: Biologic agents targeting T2 components, such as interleukins 4, 5, and 13, and IgE, offer new treatment approaches to manage severe refractory CRSwNP with or without comorbidities (e.g., asthma, atopic eczema, allergic rhinitis).